Emerging role for novel immunotherapy agents in metastatic renal cell carcinoma: from bench to bedside

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting

Volumn , Issue , 2015, Pages e291-e297

  Weinstock, Matthew ^a   McDermott, David F ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, RENAL CELL; HUMAN; IMMUNOTHERAPY; KIDNEY NEOPLASMS; PATHOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84965190017     PISSN: None     EISSN: 15488756     Source Type: Journal    
DOI: 10.14694/EdBook_AM.2015.35.e291     Document Type: Review

References (0)